UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents

Hepatology (Baltimore, Md.), 2022-09, Vol.76 (3), p.854-859

2022

Volltextzugriff (PDF)

Epidemiology of Hepatitis B and C Viruses: A Global Overview

Clinics in liver disease, 2010-02, Vol.14 (1), p.1-21

2010

Volltextzugriff (PDF)

A New Era of Hepatitis C Therapy Begins

The New England journal of medicine, 2011-03, Vol.364 (13), p.1272-1274

Jensen, Donald M

2011

Volltextzugriff (PDF)

Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)

Liver international, 2013-10, Vol.33 (9), p.1398-1405

2013

Volltextzugriff (PDF)

Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection

PLoS pathogens, 2015-12, Vol.11 (12), p.e1005325-e1005325

2015

Volltextzugriff (PDF)

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

The New England journal of medicine, 2014-04, Vol.370 (17), p.1604-1614

2014

Volltextzugriff (PDF)

Sticker shock and the price of new therapies for hepatitis C: Is it worth it?

Hepatology (Baltimore, Md.), 2014-04, Vol.59 (4), p.1246-1249

2014

Volltextzugriff (PDF)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

Drug design, development and therapy, 2019-07, Vol.13, p.2565-2577

2019

Volltextzugriff (PDF)

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy

Hepatology (Baltimore, Md.), 2006-05, Vol.43 (5), p.954-960

2006

Volltextzugriff (PDF)

Generic medications for hepatitis C

Liver international, 2016-07, Vol.36 (7), p.925-928

2016

Volltextzugriff (PDF)

Influence of ethnicity on histological differences in non-alcoholic fatty liver disease

Journal of hepatology, 2009-04, Vol.50 (4), p.797-804

2009

Volltextzugriff (PDF)

Future therapies for chronic hepatitis C

Nature reviews. Gastroenterology & hepatology, 2013-05, Vol.10 (5), p.268-276

2013

Volltextzugriff (PDF)

Ribavirin in the treatment of chronic hepatitis C

Journal of gastroenterology and hepatology, 2008-06, Vol.23 (6), p.844-855

2008

Volltextzugriff (PDF)

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b: A Randomized Trial

Annals of internal medicine, 2009-04, Vol.150 (8), p.528

Jensen, Donald M.

2009

Volltextzugriff (PDF)

Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C

Liver international, 2015-01, Vol.35 (s1), p.11-17

2015

Volltextzugriff (PDF)

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?

Liver international, 2012-02, Vol.32 (s1), p.74-78

2012

Volltextzugriff (PDF)

Vanishing Bile Duct Syndrome

Clinics in liver disease, 2008-02, Vol.12 (1), p.203-217

2008

Volltextzugriff (PDF)

Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents

Hepatology (Baltimore, Md.), 2012-12, Vol.56 (6), p.2398-2403

2012

Volltextzugriff (PDF)

Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer

BMC gastroenterology, 2016-02, Vol.16 (30), p.30-30, Article 30

2016

Volltextzugriff (PDF)

JUMP‐C: A randomized trial of mericitabine plus pegylated interferon alpha‐2a/ribavirin for 24 weeks in treatment‐naïve HCV genotype 1/4 patients

Hepatology (Baltimore, Md.), 2013-08, Vol.58 (2), p.514-523

2013

Volltextzugriff (PDF)

Response‐guided peg‐interferon plus ribavirin treatment duration in chronic hepatitis C: Meta‐analyses of randomized, controlled trials and implications for the future

Hepatology (Baltimore, Md.), 2011-09, Vol.54 (3), p.789-800

2011

Volltextzugriff (PDF)

Current State of Combined Heart–Liver Transplantation in the United States

The Journal of heart and lung transplantation, 2008-07, Vol.27 (7), p.753-759

2008

Volltextzugriff (PDF)

Sa1848 Protein Biomarkers Reactive With Hepatocellular Carcinoma (HCC) Sera Serve As a Signature for Hepatocellular Carcinoma

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-1023-S-1023

2015

Volltextzugriff (PDF)

Faster than a speeding bullet

Hepatology (Baltimore, Md.), 2014-03, Vol.59 (3), p.741-742

2014

Volltextzugriff (PDF)

Advances in combination regimens in the management of HCV infection

Gastroenterology & hepatology, 2014-02, Vol.10 (2), p.134-136

Jensen, Donald M

2014

Volltextzugriff (PDF)

1 – 25 von 1.088

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(849)
Mit Volltextzugriff
(833)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(562)
Life Sciences & Biomedicine
(448)
Humans
(334)
Male
(188)
Female
(180)
Biological And Medical Sciences
(158)
Adult
(127)
Middle Aged
(127)
Medical Sciences
(122)
Physical Sciences
(93)
Gastroenterology & Hepatology
(79)
Aged
(74)
Animals
(62)
Social Sciences
(56)
Treatment Outcome
(53)
Gastroenterology And Hepatology
(50)
Physics
(47)
Technology
(47)
Fundamental And Applied Biological Sciences. Psychology
(44)
Antiviral Agents - Therapeutic Use
(41)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents

Epidemiology of Hepatitis B and C Viruses: A Global Overview

A New Era of Hepatitis C Therapy Begins

Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)

Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Sticker shock and the price of new therapies for hepatitis C: Is it worth it?

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy

Generic medications for hepatitis C

Influence of ethnicity on histological differences in non-alcoholic fatty liver disease

Future therapies for chronic hepatitis C

Ribavirin in the treatment of chronic hepatitis C

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b: A Randomized Trial

Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?

Vanishing Bile Duct Syndrome

Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents

Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer

JUMP‐C: A randomized trial of mericitabine plus pegylated interferon alpha‐2a/ribavirin for 24 weeks in treatment‐naïve HCV genotype 1/4 patients

Response‐guided peg‐interferon plus ribavirin treatment duration in chronic hepatitis C: Meta‐analyses of randomized, controlled trials and implications for the future

Current State of Combined Heart–Liver Transplantation in the United States

Sa1848 Protein Biomarkers Reactive With Hepatocellular Carcinoma (HCC) Sera Serve As a Signature for Hepatocellular Carcinoma

Faster than a speeding bullet

Advances in combination regimens in the management of HCV infection

Suchergebnisse filtern